Richardt-Pargmann Denise, Vollmer Jörg
Coley Pharmaceutical GmbH-A Pfizer Company, Düsseldorf, Germany.
Ann N Y Acad Sci. 2009 Sep;1175:40-54. doi: 10.1111/j.1749-6632.2009.04971.x.
Most of the therapeutic applications for synthetic oligodeoxynucleotides (ODN) and oligoribonucleotides (ORN) relate to mechanisms of manipulating gene expression based on Watson-Crick base pairing to endogenous nucleic acids. However, in recent years it has become apparent that the immune system has evolved defense mechanisms against infections that are based on the detection of infecting viral and bacterial nucleic acids. In some cases, synthetic ODN and ORN can trigger these defenses and, therefore, can interfere with or distort the mechanism of action of antisense ODN or small interfering RNAs.
合成寡脱氧核苷酸(ODN)和寡核糖核苷酸(ORN)的大多数治疗应用都与基于沃森-克里克碱基配对来操纵内源性核酸的基因表达机制有关。然而,近年来已经很明显,免疫系统已经进化出针对感染的防御机制,这些机制基于对感染的病毒和细菌核酸的检测。在某些情况下,合成的ODN和ORN可以触发这些防御,因此可能会干扰或扭曲反义ODN或小干扰RNA的作用机制。